A Dose Range Finding Study With Open-Label Extension to Evaluate the Safety of Oral LMI070/Branaplam in Early Manifest Huntington's Disease

Stopped The trial was halted prematurely due to signs and symptoms that suggested the possibility of peripheral neuropathy. All participants who received branaplam continued to undergo routine (safety) evaluations for up to a year following their final dose

Conditions

• Early Manifest Huntington Disease

Interventions

• DRUG: Branaplam
• DRUG: Placebo

Sponsor

Novartis Pharmaceuticals